WallStreetZenWallStreetZen

NASDAQ: BLUE
Bluebird Bio Inc Stock

$1.37+0.17 (+14.17%)
Updated Mar 27, 2024
BLUE Price
$1.37
Fair Value Price
N/A
Market Cap
$149.24M
52 Week Low
$0.88
52 Week High
$5.53
P/E
-2.28x
P/B
0.67x
P/S
15.27x
PEG
N/A
Dividend Yield
N/A
Revenue
$21.73M
Earnings
-$91.17M
Gross Margin
-10.1%
Operating Margin
-457.81%
Profit Margin
-419.6%
Debt to Equity
1.76
Operating Cash Flow
-$277M
Beta
1.26
Next Earnings
May 7, 2024
Ex-Dividend
N/A
Next Dividend
N/A

BLUE Overview

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how BLUE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

BLUE is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
BLUE is good value based on its book value relative to its share price (0.67x), compared to the US Biotechnology industry average (6.2x)
P/B vs Industry Valuation
BLUE is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more BLUE due diligence checks available for Premium users.

Be the first to know about important BLUE news, forecast changes, insider trades & much more!

BLUE News

Valuation

BLUE fair value

Fair Value of BLUE stock based on Discounted Cash Flow (DCF)
Price
$1.37
Fair Value
$3,042.94
Undervalued by
99.95%
BLUE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

BLUE price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-2.28x
Industry
14.3x
Market
44.45x

BLUE price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.67x
Industry
6.2x
BLUE is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

BLUE's financial health

Profit margin

Revenue
$12.4M
Net Income
-$71.7M
Profit Margin
-578.8%
BLUE's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
BLUE's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$613.6M
Liabilities
$391.1M
Debt to equity
1.76
BLUE's short-term assets ($247.08M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BLUE's short-term assets ($247.08M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BLUE's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
BLUE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$61.8M
Investing
$62.1M
Financing
-$42.0k
BLUE's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

BLUE vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
BLUE$149.24M+13.75%-2.28x0.67x
GALT$149.06M+1.69%-3.17x-2.83x
CLLS$148.41M+3.89%-1.62x1.95x
CTMX$148.31M+3.79%-219.00x-3.13x
ARMP$148.21M+1.49%-2.15x-4.62x

Bluebird Bio Stock FAQ

What is Bluebird Bio's quote symbol?

(NASDAQ: BLUE) Bluebird Bio trades on the NASDAQ under the ticker symbol BLUE. Bluebird Bio stock quotes can also be displayed as NASDAQ: BLUE.

If you're new to stock investing, here's how to buy Bluebird Bio stock.

What is the 52 week high and low for Bluebird Bio (NASDAQ: BLUE)?

(NASDAQ: BLUE) Bluebird Bio's 52-week high was $5.53, and its 52-week low was $0.88. It is currently -75.32% from its 52-week high and 55.29% from its 52-week low.

How much is Bluebird Bio stock worth today?

(NASDAQ: BLUE) Bluebird Bio currently has 109,336,211 outstanding shares. With Bluebird Bio stock trading at $1.37 per share, the total value of Bluebird Bio stock (market capitalization) is $149.24M.

Bluebird Bio stock was originally listed at a price of $26.91 in Jun 19, 2013. If you had invested in Bluebird Bio stock at $26.91, your return over the last 10 years would have been -94.93%, for an annualized return of -25.78% (not including any dividends or dividend reinvestments).

How much is Bluebird Bio's stock price per share?

(NASDAQ: BLUE) Bluebird Bio stock price per share is $1.37 today (as of Mar 27, 2024).

What is Bluebird Bio's Market Cap?

(NASDAQ: BLUE) Bluebird Bio's market cap is $149.24M, as of Mar 29, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Bluebird Bio's market cap is calculated by multiplying BLUE's current stock price of $1.37 by BLUE's total outstanding shares of 109,336,211.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.